Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 2/20 | 0.59 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.54 |
| ▸ | TACR1 | P25103 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 3/20 | 0.52 |
| ▸ | CTSS | P25774 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 3/20 | 0.51 |
| ▸ | MME | P08473 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7701531 | 1.00 | CTRB1 (0.59) | CTRB1TRPM8TACR1CTSLCTSS | |
| SCHEMBL11029773 | 0.90 | CTRB1 (0.56) | CTRB1TRPM8TACR1CTSLCTSS | |
| SCHEMBL29467644 | 0.88 | CTRB1 (0.60) | CTRB1TRPM8TACR1CTSLCTSS | |
| SCHEMBL7886288 | 0.88 | CTRB1 (0.60) | CTRB1TRPM8TACR1CTSLCTSS | |
| SCHEMBL20529450 | 0.88 | CTRB1 (0.60) | CTRB1TRPM8TACR1CTSLCTSS | |
| SCHEMBL7759227 | 0.87 | ECE1 (0.62) | CTRB1CTSLCTSSCTSBCTSK | |
| SCHEMBL11785122 | 0.87 | CTSL (0.60) | CTRB1TRPM8CTSLCTSSCTSB | |
| SCHEMBL11148538 | 0.87 | MME (0.58) | CTRB1TACR1CTSLCTSSCTSB | |
| SCHEMBL7757920 | 0.86 | MME (0.59) | CTSLCTSSECE1MME | |
| SCHEMBL8909917 | 0.86 | CTRB1 (0.51) | CTRB1TRPM8CTSLCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0779296-A2 | D-alpha-aminoalkanoyl-(S)-N-alpha-alkylbenzyl amides useful as intermediates for artificial sweeteners | THE COCA-COLA COMPANY (US) | 1997-06-18 | — | — | EP | claimed |
| JP-62067098-A | — | — | None | — | — | JP | disclosed |
| JP-63039896-A | — | — | None | — | — | JP | disclosed |
| JP-4356499-A | — | — | None | — | — | JP | disclosed |
| EP-1390358-A4 | AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNE MODULATORS AND ANTICANCER AGENT | PHARMAGENESIS INC (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1390358-A1 | AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNE MODULATORS AND ANTICANCER AGENT | PHARMAGENESIS, INC. (US) | 2004-02-25 | — | — | EP | disclosed |
| US-6569893-B2 | Administering to a patient a triptolide or its derivatives, containing an amino acid or oligopeptide moiety for the treatment of cancer and autoimmune deseases, or inhibition of transplant rejection, graft versus host disease | PHARMAGENESIS, INC. | 2003-05-27 | — | — | US | disclosed |
| US-20020193419-A1 | Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents | PHARMAGENESIS, INC. | 2002-12-19 | — | — | US | disclosed |
| WO-2002074759-A1 | AMINO ACID DERIVATIVES OF TRIPTOLIDE COMPOUNDS AS IMMUNE MODULATORS AND ANTICANCER AGENT | PHARMAGENESIS, INC. (US) | 2002-09-26 | — | — | WO | disclosed |
| US-6342582-B1 | PURIFICATION AND/OR BIOSYNTHESIS OF OLIGOPEPTIDES IN PRESENCE OF A PHENOL OR MIXTURE; DEBLOCKING, AMIDATION; VACCINES, DRUGS, FOOD, AGRICULTURE | RHODIA CHIMIE (FR) | 2002-01-29 | — | — | US | disclosed |
| US-4399163-A | ARTIFICIAL SWEETENERS | PFIZER INC. (US) | 1983-08-16 | — | — | US | disclosed |
| US-4394308-A | Method of producing α-L-aspartyl-L-phenylalanine methylesters | CHIMICASA GMBH (CH) | 1983-07-19 | — | — | US | disclosed |
| EP-0069811-A1 | Branched amides of L-aspartyl-D-amino acid dipeptides and compositions thereof | PFIZER INC. (US) | 1983-01-19 | — | — | EP | disclosed |
| EP-0034876-A2 | Branched amides of L-aspartyl-D-amino acid dipeptides and compositions thereof | PFIZER INC. (US) | 1981-09-02 | — | — | EP | disclosed |
| US-4237272-A | BACTERICIDES | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1980-12-02 | — | — | US | disclosed |
| US-4217280-A | Amino-3-cardenolide derivatives, process for their preparation, and pharmaceutical compositions containing same | ETABLISSEMENTS NATIVELLE S.A. (FR) | 1980-08-12 | — | — | US | disclosed |
| US-4119493-A | IN PRESENCE OF METALLOPROTEINASE ENZYME | (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1978-10-10 | — | — | US | disclosed |
| US-4116768-A | AMIDATION, METALLOPROTEINASE ENZYME | (ZAIDANHOJIN) SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1978-09-26 | — | — | US | disclosed |
| US-4025551-A | 3-Amino-N-substituted succinamic acids | G. D. SEARLE & CO. (US) | 1977-05-24 | — | — | US | disclosed |
| US-4011260-A | 3-AMINO-N-SUBSTITUTED SUCCINAMIC ACIDS AND INTERMEDIATES THERETO | G. D. SEARLE & CO. (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193419-A1 | Amino acid derivatives of triptolide compounds as immune modulators and anticancer agents | CCRL2, CCR1, XPNPEP1 | CTRB1 1072/4885TRPM8 4028/4885TACR1 2932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.